Compare Cassava Sciences Inc (FLNA) vs Wells Fargo & Co (WFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Wells Fargo & Co — how do they compare? Cassava Sciences Inc trades at $0.97 (market cap $47.75M), while Wells Fargo & Co trades at $87.5 (market cap $264.66B). The key difference: Wells Fargo & Co is far larger — about 5542.6× Cassava Sciences Inc's market cap, and Wells Fargo & Co pays a 2.29% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | WFC | |
|---|---|---|
Market Cap | $47.75M | $264.66B |
Sector | Health | Financials |
52-Week High | $4.64 | $96.40 |
52-Week Low | $0.87 | $73.42 |
Enterprise Value | -$34.93M | — |
Dividend Yield | — | 2.29% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.995, up 3.75% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of -$0.18 beating expectations of -$0.225. Financials show negative cash flows and profitability, with ROE at -55.79% and net income of -$90.97M in 2025. Analyst consensus is strongly positive with 8 buy ratings out of 12.
Despite operational losses, FLNA's consistent earnings beats and strong analyst support suggest potential upside if clinical developments progress. Key risks include sustained cash burn, lack of revenue, and dependence on successful drug trials for Tuberous Sclerosis Complex. The stock remains speculative with high volatility expected.
Wells Fargo (WFC) trades at $87.25, down 0.4% today, with a bullish technical outlook from moving averages and a consensus price target of $97.64. The stock shows strong profitability with a net income margin of 25.97% and ROE of 13.13%, supported by steady revenue growth to $83.70 billion in 2025. Recent news highlights the launch of tokenized deposits for corporate clients, reflecting innovation in digital banking services.
The stock presents a value opportunity with a P/E of 12.68, but risks include volatile cash flows and recent earnings misses. Upside is driven by analyst optimism and dividend increases, while headwinds involve economic sensitivity and competitive pressures in banking.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Wells Fargo & Co
Wells Fargo is one of the largest banks in the United States, with approximately $1.9 trillion in balance sheet assets. The company is split into four primary segments: consumer banking, commercial banking, corporate and investment banking, and wealth and investment management. It is almost entirely focused on the U.S.
Read more on WFC →
